Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Sponsored content

Contributory infringement: an Australian patent primer

Sponsored by


Stefania Sassnink and Paul Whenman of FB Rice provide a guide to when third parties can be held responsible for patent infringement on the basis of supplying a product

Direct versus contributory infringement

Direct infringement is usually easily identified and pursued – someone produces, sells, or uses a product and, by doing so, infringes a patent. But what is available to a patentee when someone does not directly infringe a patent but ‘only’ contributes to the patent infringement by supplying a patented product?

Contributory infringement, also known as indirect infringement or infringement by supply, was implemented in Section 117 of the Patents Act 1990 (Cth) (the ‘Act’) to permit a patentee to hold the supplier responsible when the direct infringer is the end user.

This provision aims to protect a patentee from infringement by a third party through the supply of a product that can only be used in an infringing way. For this section to apply, at least one of these criteria must be met:

  • The supplied product is only capable of one reasonable use;

  • The product is not a ‘staple commercial product’ and the supplier had ‘reason to believe’ that the end user would use it in an infringing way; and/or

  • The product is supplied with explicit instructions to use it in an infringing way.

Staple commercial products

A notable exception to this provision is when the product is classified as a staple commercial product. There is no definition in the Act for a staple commercial product but recent case law provides some guidance.

In Northern Territory of Australia v. Collins [2008] HCA 49, the High Court of Australia concluded that a staple commercial product is a product that is generally available and supplied commercially for a variety of uses.

In Hood v. Down Under Enterprises International Pty Limited [2022] FCAFC 69, [53]–[57], the primary judge expanded on this definition and gave four reasons why the product in question (an essential oil obtained from the shrub Kunzea ambigua) was considered a staple commercial product.

First, the oil is a raw material commercially supplied for a range of uses. Second, the oil can be, and in fact is, used for a range of non-infringing purposes. Third, the oil had been registered on the Australian Register of Therapeutic Goods for a wide range of medical indications and not all these indications had been covered in the claims. And fourth, the crucial question is whether the product is supplied for various purposes.

Since the court concluded that the product is a staple commercial product, no indirect infringement had occurred by supplying it. To prove contributory infringement, the patentee would have had to show that the oil had been supplied with explicit instructions to use the product in an infringing way.

Second medical use claims

Contributory infringement is especially relevant in the context of known pharmaceutical products in second medical use patents. Since pharmaceutical products are rarely considered to be staple commercial products (see, for instance, AstraZeneca AB v. Apotex Pty Ltd [2014] FCAFC 99), the court will consider if the pharmaceutical product can only be used in an infringing way or if the supplier had reason to believe that the product would be used in an infringing way.

Swiss-type claims are commonly used alongside method of treatment claims in second medical use patents since the Full Federal Court of Australia concluded, in Mylan Health Pty Ltd v. Sun Pharma ANZ Pty Ltd [2020] FCAFC 116, that both claim types offer a slightly different scope of protection. With regard to infringement, the court has taken a clear position regarding Swiss-type claims, stating that the manufacturer’s intention in making the medicament is irrelevant.

Determining infringement of a method of treatment claim is less transparent. However, there are some considerations that can be used as guidance. The court determined that the main question is if the manufacturer had reason to believe that a medical practitioner would prescribe the generic drug instead of the original drug for the patented indication.

For this assessment, the court will compare the physical characteristics of the generic product, such as the formulation and dosage, and how big the markets of the patented and non-patented indications are. By doing so, the court warns generic manufacturers that it may not be enough to simply carve out specific patented indications from the product information (PI), a practice known as ‘skinny labelling’, if there is reason to believe that the generic drug could be used in an infringing way.

The main considerations

In deciding the merits of pursuing a third party for contributory infringement, a key consideration will be whether the product is a staple commercial product. If yes, the supply will only be infringing if specific instructions to use the product in an infringing way are supplied with the product.

With regard to second medical use patents and pharmaceutical products, infringement has to be decided on a case-by-case basis, but the main consideration is to determine if the generic manufacturer had reason to believe that the product will be used in an infringing way.

more from across site and ros bottom lb

More from across our site

Counsel are eying domestic industry, concurrent PTAB proceedings and heightened scrutiny of cases before institution
Jack Daniel’s has a good chance of winning its dispute over dog toys, but SCOTUS will still want to protect free speech, predict sources
AI users and lawyers discuss why the rulebook for registering AI-generated content may create problems and needs further work
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
A technical effect must still be evident in the original patent filing, the EBoA said in its G2/21 decision today, March 23
Brands should not be deterred from pursuing lookalike producers, and an unfair advantage claim could be the key, say Emma Teichmann and Geoff Steward at Stobbs
Justice Mellor’s highly anticipated ruling surprised SEP owners and reassured implementers that the UK may not be so hostile after all
The England and Wales High Court's judgment comes ahead of a separate hearing concerning one of the patents-in-suit at the EPO
While the rules allow foreign firms to open local offices and offer IP services, a ban on litigation and practising Indian law could mean little will change
A New York federal court heard oral arguments this week in a copyright case pitting publishing giants against a digital library